KDM6A and acute myeloid leukemia: In addition, KDM6A/B were implicated in DNA damage response in acute myeloid leukemia (AML) cells, and the loss of KDM6A sensitized cells to poly (ADP-ribose) polymerase (PARP) inhibition using olaparib, pointing to a possibility of synthetic lethality between KDM6A loss-of-function mutations—which are observed in AML patients—and pharmacological inhibition of PARP [203].